[Surgical therapeutic approach with the burn patient].

D. Jacquemin

1989-09-01

Abstract:

What problem does this paper attempt to address?

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Eliane Klein,Ann-Christin Hau,Anaïs Oudin,Anna Golebiewska,Simone P Niclou

DOI: https://doi.org/10.3389/fonc.2020.604121

2020-12-08

Abstract:Malignant brain tumors remain uniformly fatal, even with the best-to-date treatment. For Glioblastoma (GBM), the most severe form of brain cancer in adults, the median overall survival is roughly over a year. New therapeutic options are urgently needed, yet recent clinical trials in the field have been largely disappointing. This is partially due to inappropriate preclinical model systems, which do not reflect the complexity of patient tumors. Furthermore, clinically relevant patient-derived models recapitulating the immune compartment are lacking, which represents a bottleneck for adequate immunotherapy testing. Emerging 3D organoid cultures offer innovative possibilities for cancer modeling. Here, we review available GBM organoid models amenable to a large variety of pre-clinical applications including functional bioassays such as proliferation and invasion, drug screening, and the generation of patient-derived orthotopic xenografts (PDOX) for validation of biological responses in vivo. We emphasize advantages and technical challenges in establishing immunocompetent ex vivo models based on co-cultures of GBM organoids and human immune cells. The latter can be isolated either from the tumor or from patient or donor blood as peripheral blood mononuclear cells (PBMCs). We also discuss the challenges to generate GBM PDOXs based on humanized mouse models to validate efficacy of immunotherapies in vivo. A detailed characterization of such models at the cellular and molecular level is needed to understand the potential and limitations for various immune activating strategies. Increasing the availability of immunocompetent GBM models will improve research on emerging immune therapeutic approaches against aggressive brain cancer.
Pre-Clinical Models for CAR T-Cell Therapy for Glioma

Gust Vandecandelaere,Rishab Ramapriyan,Matthew Gaffey,Leland Geoffrey Richardson,Samuel Jeffrey Steuart,Masih Tazhibi,Adrian Kalaw,Eric P. Grewal,Jing Sun,William T. Curry,Bryan D. Choi

DOI: https://doi.org/10.3390/cells13171480

IF: 6

2024-09-05

Cells

Abstract:Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor. Research leveraging CAR T-cell therapy for brain tumors has surged in recent years. Pre-clinical models are crucial in evaluating the safety and efficacy of these therapies before they advance to clinical trials. However, current models recapitulate the human tumor environment to varying degrees. Novel in vitro and in vivo techniques offer the opportunity to validate CAR T-cell therapies but also have limitations. By evaluating the strengths and weaknesses of various pre-clinical glioma models, this review aims to provide a roadmap for the development and pre-clinical testing of CAR T-cell therapies for brain tumors.

cell biology
A Practical Receiver Structure for Multi-h CPM Signals

A. Premji,Desmond P. Taylor

DOI: https://doi.org/10.1109/TCOM.1987.1096885

IF: 6.166

1987-09-01

IEEE Transactions on Communications

Abstract:Multi- h schemes are bandwidth-efficient CPM signaling formats which offer means of coding without explicit redundancy. However, the required (optimal) receiver structures tend to be very complex [1], [4], [8] requiring a large number of filters of correlators. Here a reduced complexity receiver for the joint estimation of M -ary data, carrier phase, and symbol timing is realized through the use of an approximate representation of the likelihood function. Evaluation of receiver performance indicates a fraction of a decibel degradation in coding gain and almost no loss in synchronization performance.
Description by quasi elastic laser light scattering of a biological preparation: Sarcoplasmic reticulum vesicles

B. Arrio,J. Chevallier,M. Jullien,J. Yon,R. Calvayrac

DOI: https://doi.org/10.1007/BF01870105

Abstract:
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

Alexander F Haddad,Jacob S Young,Dominic Amara,Mitchel S Berger,David R Raleigh,Manish K Aghi,Nicholas A Butowski

DOI: https://doi.org/10.1093/noajnl/vdab100

2021-01-01

Abstract:Abstract Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15 months despite an aggressive standard of care that includes surgery, chemotherapy, and ionizing radiation. Mouse models have advanced our understanding of GBM biology and the development of novel therapeutic strategies for GBM patients. However, model selection is crucial when testing developmental therapeutics, and each mouse model of GBM has unique advantages and disadvantages that can influence the validity and translatability of experimental results. To shed light on this process, we discuss the strengths and limitations of 3 types of mouse GBM models in this review: syngeneic models, genetically engineered mouse models, and xenograft models, including traditional xenograft cell lines and patient-derived xenograft models.

English Else
Expression of murine mammary tumor virus-related antigens in human breast carcinoma (MCF-7) cells.

N. Yang,H. Soule,C. Mcgrath

DOI: https://doi.org/10.1093/JNCI/59.5.1357

1977-11-01

Journal of the National Cancer Institute

Abstract:
Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies

A. J. Schuhmacher,M. Squatrito

DOI: https://doi.org/10.1007/978-3-319-56820-1_9

2017-01-01

Abstract:The gliomas are a large group of brain tumors and Glioblastoma Multiforme (GBM) is the most common and lethal primary central nervous system tumor in adults. Despite the recent advances in treatment modalities, GBM patients generally respond poorly to all therapeutic approaches and prognosis remain dismal. Gaining insights into the pathways that determine this poor treatment response and the generation of more relevant animal models that recapitulate a patient’s tumor will be instrumental for the elaboration of new therapeutic modalities.Here we will focus on the available animal models for adult GBM and their use in preclinical drug development. We will be examining the recent advances in genetically engineered mouse models and discuss how such models may offer specific advantages over cell culture and xenograft systems for validating drug targets and prioritizing candidates for clinical trials. Lastly we will briefly examine the clinical relevance in glioma research of other animal models such as fruit fly, zebrafish and canine.
Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

Upasana Sahu,Rolf F Barth,Yoshihiro Otani,Ryan McCormack,Balveen Kaur

DOI: https://doi.org/10.1093/jnen/nlac021

2022-04-21

Abstract:Abstract Rodent brain tumor models have been useful for developing effective therapies for glioblastomas (GBMs). In this review, we first discuss the 3 most commonly used rat brain tumor models, the C6, 9L, and F98 gliomas, which are all induced by repeated injections of nitrosourea to adult rats. The C6 glioma arose in an outbred Wistar rat and its potential to evoke an alloimmune response is a serious limitation. The 9L gliosarcoma arose in a Fischer rat and is strongly immunogenic, which must be taken into consideration when using it for therapy studies. The F98 glioma may be the best of the 3 but it does not fully recapitulate human GBMs because it is weakly immunogenic. Next, we discuss a number of mouse models. The first are human patient-derived xenograft gliomas in immunodeficient mice. These have failed to reproduce the tumor-host interactions and microenvironment of human GBMs. Genetically engineered mouse models recapitulate the molecular alterations of GBMs in an immunocompetent environment and “humanized” mouse models repopulate with human immune cells. While the latter are rarely isogenic, expensive to produce, and challenging to use, they represent an important advance. The advantages and limitations of each of these brain tumor models are discussed. This information will assist investigators in selecting the most appropriate model for the specific focus of their research.

pathology,neurosciences,clinical neurology
Immu-66. Physiologically Relevant Murine Glioma Models That Represent Gbm Heterogeneity And Enable The Next Generation Of Discovery And Therapy Efficacy Studies

Jose Maldonado,Caiyi Wang,Jia-Shiun Leu,Han Nhat Tran,Nourhan Abdelfattah,Kyuson Yun

DOI: https://doi.org/10.1093/neuonc/noae165.0658

2024-11-29

Neuro-Oncology

Abstract:To transform cancer drug development pipelines and gain a deeper mechanistic understanding of cancer: immune interactions, we desperately need better experimental models that faithfully recapitulate the cellular heterogeneity, complex and dynamic cell:cell interactions, and therapy responses in humans. To address this need, we developed and characterized a cohort of five new mouse glioma models in the C57BL6/j background. These transplantable tumorsphere models were derived from spontaneous gliomas that formed in genetically engineered mouse models with different oncogenic drivers, including EGFRviii, PDGFA, PTEN, p53, and NF1 mutations. They show a range of responses to standard of care (TMZ+IR) similar to GBM patients and all are resistant, to immune checkpoint inhibitors, anti-PD1+CTLA4, treatment, unlike the GL261 model and similar to GBM patients. We deeply characterized each model, including immune phenotyping and single-cell RNA-sequencing analyses. We also performed a cross-species comparison of human and mouse GBM and stromal cell phenotypes at the single-cell level. Our results show that new mouse models recapitulate the heterogeneity of glioma cell states observed in individual patients and, importantly, also the complex and immune suppressive TME. We demonstrate at the single-cell level that glioma-associated T and myeloid cell types are molecularly similar and conserved across species. Leveraging these data sets and experimental models, we are testing now novel immunotherapy targets for GBM.

oncology,clinical neurology
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation

Till Milde,Jason Fangusaro,Michael J Fisher,Cynthia Hawkins,Fausto J Rodriguez,Uri Tabori,Olaf Witt,Yuan Zhu,David H Gutmann

DOI: https://doi.org/10.1093/neuonc/noad125

2023-11-02

Abstract:Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in young children. While they are typically associated with good overall survival, children with these central nervous system tumors often experience chronic tumor- and therapy-related morbidities. Moreover, individuals with unresectable tumors frequently have multiple recurrences and persistent neurological symptoms. Deep molecular analyses of pLGGs reveal that they are caused by genetic alterations that converge on a single mitogenic pathway (MEK/ERK), but their growth is heavily influenced by nonneoplastic cells (neurons, T cells, microglia) in their local microenvironment. The interplay between neoplastic cell MEK/ERK pathway activation and stromal cell support necessitates the use of predictive preclinical models to identify the most promising drug candidates for clinical evaluation. As part of a series of white papers focused on pLGGs, we discuss the current status of preclinical pLGG modeling, with the goal of improving clinical translation for children with these common brain tumors.
Tmod-33. Does Pre-Clinical Drug Activity Predict Phase Ii Clinical Efficacy In Glioblastoma? A Detailed Analysis

Arman T Zadeh,Elliot J Crooks,Josephine Volovetz,Anthony R Sloan,Justin D Lathia,Andrew Dhawan

DOI: https://doi.org/10.1093/neuonc/noae165.1297

2024-11-29

Neuro-Oncology

Abstract:Despite decades of research, there are fewer than six FDA-approved therapies for glioblastoma (GBM). The drug approval process relies on studies establishing pre-clinical activity, most commonly using murine models, followed by in human studies establishing safety and then efficacy. Although murine models for GBM have allowed for insights into tumor biology, their utility in assessing the efficacy of novel anti-cancer therapies remains highly debated. Here, we sought to establish whether there was any relationship between drug activity in preclinical models and phase 2 clinical trial outcomes. Using ClinicalTrials.gov (NIH), all phase 2 trials in glioblastoma up to December 2023 were queried and downloaded. Trials that were never started, had not yet started, were withdrawn, not completed, or contained indications beyond glioblastoma were excluded. Studies examining anti-tumor effects of an investigational agent with or without bevacizumab, temozolomide, or radiation therapy in glioblastoma were included, and studies examining alternative dosing strategies, various medical devices, or drug combinations, were excluded. The corresponding preclinical studies were identified via literature review for each clinical trial. Data including the progression free and overall survival benefit, mouse models used, and sample sizes were extracted from each study. 659 trials between 1994 and 2023 were included for analysis. Of these, 272 (41%) were for monotherapies, examining 90 unique small molecules. Preclinical endpoints included murine survival and tumor weight. In comparing mouse survival and tumor size to progression free and overall survival in humans, our preliminary analysis did not reveal any clear correlation. The correlation between preclinical and clinical drug response in GBM remains uncertain. Future work will examine whether mouse genotype, immune status, or GBM cell line used affected the degree of concordance with human clinical trial data. Our analysis suggests that further investigation into preclinical models of GBM, and standardized reporting of preclinical models, are needed.

oncology,clinical neurology
Glioma: experimental models and reality

Krissie Lenting,Roel Verhaak,Mark ter Laan,Pieter Wesseling,William Leenders

DOI: https://doi.org/10.1007/s00401-017-1671-4

IF: 15.887

2017-01-10

Acta Neuropathologica

Abstract:In theory, in vitro and in vivo models for human gliomas have great potential to not only enhance our understanding of glioma biology, but also to facilitate the development of novel treatment strategies for these tumors. For reliable prediction and validation of the effects of different therapeutic modalities, however, glioma models need to comply with specific and more strict demands than other models of cancer, and these demands are directly related to the combination of genetic aberrations and the specific brain micro-environment gliomas grow in. This review starts with a brief introduction on the pathological and molecular characteristics of gliomas, followed by an overview of the models that have been used in the last decades in glioma research. Next, we will discuss how these models may play a role in better understanding glioma development and especially in how they can aid in the design and optimization of novel therapies. The strengths and weaknesses of the different models will be discussed in light of genotypic, phenotypic and metabolic characteristics of human gliomas. The last part of this review provides some examples of how therapy experiments using glioma models can lead to deceptive results when such characteristics are not properly taken into account.

pathology,neurosciences,clinical neurology
Advances in glioma therapy and its animal models

Zhen-zhen YANG,Yu-jie LIU,Xian-rong QI

DOI: https://doi.org/10.13506/j.cnki.jpr.2014.10.001

2014-01-01

Journal of Pharmaceutical Research

Abstract:Glioma is the most common and deadly tumor in primary CNS tumors. Despite an increasing emphasis on developing new therapies for malignant gliomas,they are still among the most intractable tumors nowadays. Numerous candidate drugs fail at late stages in their clinical trials,after showing promising preclinical results,which prompt the essential of improving animal models for evaluation. With the development of pharmacology,pharmaceutics and molecular biology,new approaches need more scientific,repeatable animal models for understanding the pathogenesis of glioma and the evaluation of drug efficacy. This review presented recent development in methods of treating glioma and animal modeling of glioma.
Establishment of an orthotopic glioblastoma mouse model for preclinical studies

Nerea Iturrioz-Rodríguez,Federica Piccardi,Rosalia Bertorelli,Gianni Ciofani

DOI: https://doi.org/10.1016/bs.mcb.2024.02.004

2024-03-23

Methods in Cell Biology

Abstract:Glioblastoma accounts almost 50% of all brain cancers, being the most common and lethal brain tumor in adults. Despite the current standard gold treatment based on surgery, chemotherapy, and radiotherapy, other treatment strategies are needed. Different in vitro models are currently used, including commercial cell lines, patient-derived cell lines, organoids, as well as in vivo models, being orthotopic xenografts the most used ones. In this chapter, we describe a standard protocol for the intracranial inoculation of glioblastoma cells in immunodeficient mice, and how to follow up the tumor progression and analyze the data.

cell biology
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies

Maria B. Garcia-Fabiani,Santiago Haase,Andrea Comba,Stephen Carney,Brandon McClellan,Kaushik Banerjee,Mahmoud S. Alghamri,Faisal Syed,Padma Kadiyala,Felipe J. Nunez,Marianela Candolfi,Antonela Asad,Nazareno Gonzalez,Marisa E. Aikins,Anna Schwendeman,James J. Moon,Pedro R. Lowenstein,Maria G. Castro

DOI: https://doi.org/10.3389/fonc.2021.631037

IF: 4.7

2021-06-08

Frontiers in Oncology

Abstract:High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits a survival rate of 14-17 months. Thus, there is an urgent need to develop new therapeutic strategies for these malignant brain tumors. Currently, immunotherapies represent an appealing approach to treat malignant gliomas, as the pre-clinical data has been encouraging. However, the translation of the discoveries from the bench to the bedside has not been as successful as with other types of cancer, and no long-lasting clinical benefits have been observed for glioma patients treated with immune-mediated therapies so far. This review aims to discuss our current knowledge about gliomas, their molecular particularities and the impact on the tumor immune microenvironment. Also, we discuss several murine models used to study these therapies pre-clinically and how the model selection can impact the outcomes of the approaches to be tested. Finally, we present different immunotherapy strategies being employed in clinical trials for glioma and the newest developments intended to harness the immune system against these incurable brain tumors.

oncology
Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy

Tatiana A. Mishchenko,Victoria D. Turubanova,Ekaterina N. Gorshkova,Olga Krysko,Maria V. Vedunova,Dmitri V. Krysko

DOI: https://doi.org/10.3389/fimmu.2023.1299064

IF: 7.3

2024-01-11

Frontiers in Immunology

Abstract:Glioma is the most common primary brain tumor, characterized by a consistently high patient mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial evidence underscores the vital role of the immune system in eradicating tumors effectively and preventing metastasis, underscoring the importance of cancer immunotherapy which could potentially address the challenges in glioma therapy. Although glioma immunotherapies have shown promise in preclinical and early-phase clinical trials, they face specific limitations and challenges that have hindered their success in further phase III trials. Resistance to therapy has been a major challenge across many experimental approaches, and as of now, no immunotherapies have been approved. In addition, there are several other limitations facing glioma immunotherapy in clinical trials, such as high intra- and inter-tumoral heterogeneity, an inherently immunosuppressive microenvironment, the unique tissue-specific interactions between the central nervous system and the peripheral immune system, the existence of the blood-brain barrier, which is a physical barrier to drug delivery, and the immunosuppressive effects of standard therapy. Therefore, in this review, we delve into several challenges that need to be addressed to achieve boosted immunotherapy against gliomas. First, we discuss the hurdles posed by the glioma microenvironment, particularly its primary cellular inhabitants, in particular tumor-associated microglia and macrophages (TAMs), and myeloid cells, which represent a significant barrier to effective immunotherapy. Here we emphasize the impact of inducing immunogenic cell death (ICD) on the migration of Th17 cells into the tumor microenvironment, converting it into an immunologically “hot” environment and enhancing the effectiveness of ongoing immunotherapy. Next, we address the challenge associated with the accurate identification and characterization of the primary immune profiles of gliomas, and their implications for patient prognosis, which can facilitate the selection of personalized treatment regimens and predict the patient’s response to immunotherapy. Finally, we explore a prospective approach to developing highly personalized vaccination strategies against gliomas, based on the search for patient-specific neoantigens. All the pertinent challenges discussed in this review will serve as a compass for future developments in immunotherapeutic strategies against gliomas, paving the way for upcoming preclinical and clinical research endeavors.

immunology
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes

Nicholas Mikolajewicz,Nazanin Tatari,Jiarun Wei,Neil Savage,Adrian Granda Farias,Vassil Dimitrov,David Chen,Zsolt Zador,Kuheli Dasgupta,Magali Aguilera-Uribe,Yu-Xi Xiao,Seon Yong Lee,Patricia Mero,Dillon McKenna,Chitra Venugopal,Kevin R. Brown,Hong Han,Sheila Singh,Jason Moffat

DOI: https://doi.org/10.1007/s00401-024-02831-w

IF: 15.887

2024-11-28

Acta Neuropathologica

Abstract:Cancer-intrinsic immune evasion mechanisms and pleiotropy are a barrier to cancer immunotherapy. This is apparent in certain highly fatal cancers, including high-grade gliomas and glioblastomas (GBM). In this study, we evaluated two murine syngeneic glioma models (GL261 and CT2A) as preclinical models for human GBM using functional genetic screens, single-cell transcriptomics and machine learning approaches. Through CRISPR genome-wide co-culture killing screens with various immune cells (cytotoxic T cells, natural killer cells, and macrophages), we identified three key cancer-intrinsic evasion mechanisms: NFκB signaling, autophagy/endosome machinery, and chromatin remodeling. Additional fitness screens identified dependencies in murine gliomas that partially recapitulated those seen in human GBM (e.g., UFMylation). Our single-cell analyses showed that different glioma models exhibited distinct immune infiltration patterns and recapitulated key immune gene programs observed in human GBM, including hypoxia, interferon, and TNF signaling. Moreover, in vivo orthotopic tumor engraftment was associated with phenotypic shifts and changes in proliferative capacity, with murine tumors recapitulating the intratumoral heterogeneity observed in human GBM, exhibiting propensities for developmental- and mesenchymal-like phenotypes. Notably, we observed common transcription factors and cofactors shared with human GBM, including developmental ( Nfia and Tcf4 ), mesenchymal ( Prrx1 and Wwtr1 ), as well as cycling-associated genes ( Bub3 , Cenpa , Bard1 , Brca1 , and Mis18bp1 ). Perturbation of these genes led to reciprocal phenotypic shifts suggesting intrinsic feedback mechanisms that balance in vivo cellular states. Finally, we used a machine-learning approach to identify two distinct immune evasion gene programs, one of which represents a clinically-relevant phenotype and delineates a subpopulation of stem-like glioma cells that predict response to immune checkpoint inhibition in human patients. This comprehensive characterization helps bridge the gap between murine glioma models and human GBM, providing valuable insights for future therapeutic development.

pathology,neurosciences,clinical neurology
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies

Iva Simeonova,Emmanuelle Huillard

DOI: https://doi.org/10.1007/s00018-014-1675-3

IF: 8

2014-07-10

Cellular and Molecular Life Sciences

Abstract:Although our knowledge of the biology of brain tumors has increased tremendously over the past decade, progress in treatment of these deadly diseases remains modest. Developing in vivo models that faithfully mirror human diseases is essential for the validation of new therapeutic approaches. Genetically engineered mouse models (GEMMs) provide elaborate temporally and genetically controlled systems to investigate the cellular origins of brain tumors and gene function in tumorigenesis. Furthermore, they can prove to be valuable tools for testing targeted therapies. In this review, we discuss GEMMs of brain tumors, focusing on gliomas and medulloblastomas. We describe how they provide critical insights into the molecular and cellular events involved in the initiation and maintenance of brain tumors, and illustrate their use in preclinical drug testing.

cell biology,biochemistry & molecular biology
Abstract 1441: Establishing a novel clinically relevant disease model of glioblastoma

Kate Connor,Kieron White,James Clerkin,Kieron Sweeney,Liam Shiels,Thomas van Brussel,Ingrid Arijs,Diether Lambrechts,Gautam Shankar,Frederik de Smet,Stephen G. Maher,Laure Marignol,Patrick Dicker,Jochen Prehn,David O'Brien,Annette T. Byrne

DOI: https://doi.org/10.1158/1538-7445.am2024-1441

IF: 11.2

2024-03-23

Cancer Research

Abstract:Introduction: GBM is the most common primary malignancy of the CNS. Historically pre-clinical models have failed to predict response in humans, despite promising preclinical data. Moreover, current models seldom incorporate surgical resection and/or standard of care chemotherapy treatment. These models also commonly employ young animals exclusively, whose immune contexture differs from older patients. We therefore sought to establish an improved, orthotopic, preclinical GBM model, which better recapitulates patient response to standard-of-care and targeted treatments. Methods: NFpp10a-Luc2 GBM cells were orthotopically implanted into C57BL/6-mice (aged[>18months] and young[6-8weeks]) and weekly bioluminescence imaging performed to monitor tumor growth. Overall survival (OS) and tumor growth were assessed in response to (1) Surgical Resection, (2) Temozolomide (TMZ) (3) anti-PD1 (4) neoadjuvant anti-PD1 and (5) Regorafenib (REGO) therapy. Tissue collected post-mortem underwent bulk RNA sequencing followed by analysis via microenvironment cell population counter (MCP) and gene set enrichment (GSEA) to determine changes in the GBM-TME following treatment. Results: We demonstrated OS advantage in aged mice undergoing surgical resection (Resection:33.5 days vs Non-Resection: 18 days; p=0.0166) and observed age to be a significant prognostic factor (Young:62 days vs Aged: 22 days; p=0.0002). Subsequently, we observed that TMZ and anti-PD1 monotherapies had no impact on NFpp10-Luc2 growth (p=0.9001, p=0.7933) or survival (p=0.3035, p=0.6328). Neoadjuvant anti-PD1 treated mice demonstrated no significant survival advantage compared to IgG control (33 days vs 35 days; p=0.9429). Lastly, REGO treatment demonstrated a trend towards improved OS vs Vehicle (p=0.096). MCP analysis revealed both neoadjuvant anti-PD1 and REGO treatment induced influx of CD8+ T cells, B cells and monocytes into the TME, with neoadjuvant anti-PD1 associated with an upregulation of CXCR3 (p=0.0045). Conclusions: We have, for the first time, established and characterized response of the NFpp10a-C57BL/6 model to surgical resection, TMZ, anti-PD1 and REGO therapy in both young and aged mice. We have shown the model is markedly insensitive to intervention with chemotherapy and immune checkpoint therapy, mirroring what is seen clinically in patients. The model may therefore be employed in future pre-clinical studies to guide clinical trials in the setting of mesenchymal GBM. Citation Format: Kate Connor, Kieron White, James Clerkin, Kieron Sweeney, Liam Shiels, Thomas van Brussel, Ingrid Arijs, Diether Lambrechts, Gautam Shankar, Frederik de Smet, Stephen G. Maher, Laure Marignol, Patrick Dicker, Jochen Prehn, David O'Brien, Annette T. Byrne. Establishing a novel clinically relevant disease model of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1441.

oncology
Clinical and Translational Advances in Glioma Immunotherapy

Lukas Bunse,Theresa Bunse,Christopher Krämer,Yu-Chan Chih,Michael Platten

DOI: https://doi.org/10.1007/s13311-022-01313-9

IF: 6.088

2022-10-29

Neurotherapeutics

Abstract:Gliomas are highly treatment refractory against immune checkpoint blockade, an immunotherapeutic modality that revolutionized therapy for many tumors. At the same time, technological innovation has dramatically accelerated the development of immunotherapeutic approaches such as personalized tumor-specific vaccine production, dendritic cell vaccine manufacture, patient-individual target selection and chimeric antigen receptor, and T cell receptor T cell manufacture. Here we review recent clinical and translational advances in glioma immunotherapy with a focus on targets and their cognate immune receptor derivates as well as concepts to improve intratumoral T cell effector functions.

pharmacology & pharmacy,neurosciences,clinical neurology

[Surgical therapeutic approach with the burn patient].

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Pre-Clinical Models for CAR T-Cell Therapy for Glioma

A Practical Receiver Structure for Multi-h CPM Signals

Description by quasi elastic laser light scattering of a biological preparation: Sarcoplasmic reticulum vesicles

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

Expression of murine mammary tumor virus-related antigens in human breast carcinoma (MCF-7) cells.

Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies

Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

Immu-66. Physiologically Relevant Murine Glioma Models That Represent Gbm Heterogeneity And Enable The Next Generation Of Discovery And Therapy Efficacy Studies

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation

Tmod-33. Does Pre-Clinical Drug Activity Predict Phase Ii Clinical Efficacy In Glioblastoma? A Detailed Analysis

Glioma: experimental models and reality

Advances in glioma therapy and its animal models

Establishment of an orthotopic glioblastoma mouse model for preclinical studies

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies

Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies

Abstract 1441: Establishing a novel clinically relevant disease model of glioblastoma

Clinical and Translational Advances in Glioma Immunotherapy